末端Galβ1-4 GlcNAc 多糖分子在肿瘤患者血清中的表达

 目的 研究末端Galβ1—4GlcNAc多糖分子在鼻咽癌、肺癌、肝癌和结直肠癌患者血清中的表达规律。方法 应用RCAⅠ（蓖麻凝集素Ⅰ）亲和层析法从正常人血清中获得RCAI相关末端Galβ1—4GlcNAC糖蛋白，用辣根过氧化物酶标记，采用凝集素差减法，对133例肿瘤患者，64例良性疾病患者和240例正常人血清进行检测。结果 鼻咽癌、肝癌和结直肠癌患者血清中RCAⅠ识别的多糖分子明显高于正常人和良性疾病患者，阳性率分别为66．7％、73．9％、64．9％；肺癌患者血清阳性率为19．4％。且在鼻咽癌和结直肠癌患者有效治疗后该多糖分子水平显著下降，阳性率也下降。结论 血清中RCAⅠ相关的末端Galβ1—4GlcNAc多糖分子，可用于肿瘤患者血清糖基化异常和肿瘤发病机制的研究，并可为临床诊断和治疗效果的评价提供参考指标。

Investigation of Expression of the Terminal Galbeta1-4GlcNAc Related Polysaccharide in Serum of Malignant Tumors Patients

Objective 　To detect the expression of the terminal Galbeta1-4 GlcNAc related polysa- ccharide in serum of nasopharyngeal carcinoma ,primary liver cancer , and colorectal cancer and lung cancer patients. Methods 　The RCA Ⅰidentifying Terminal Galβ1-4 GlcNAc glycoprotein was acquired by RCA Ⅰ(Ricinus communis agglutinin Ⅰ) affinity chromatography method f rom normal person serum and was marked by the horseradish peroxidase. 133 tumor patient s ,64 benign disease patient s and 240 normal person serums were detected by the subt raction of agglutinin. Results 　The polysaccharide level of the RCAⅠidentification in serum of nasopharyngeal carcinoma ,primary liver cancer and colorectal cancer was obvious higher than it in normal person and benign disease patient s. The positive rate was 66. 7 % ,73. 9 % and 64. 9 % relatively. Lung cancer had only positive rate 19. 4 %. After effective therapy , the polysac-charide lever of the RCA Ⅰidentification in serum of nasopharyngeal carcinoma and colorectal cancer remarkably descent ,the positive rate also descent . Conclusion 　The terminal Galbeta124 GlcNAc related polysac-charide in serum can be applied to the research of abnormal polysaccharide in tumor patient and pathogenesis. It s level can provide reference for clinical diagnosis and the evaluation on curative effect .